Date: 2018-10-31

Type of information: Licensing agreement

Compound: AAV-AQP1

Company: MeiraGTx (USA - NY) National Institute of Dental and Craniofacial Research (NIDCR) (USA)

Therapeutic area: Rare diseases

Type agreement: licensing

Action mechanism: gene therapy.

Disease: Sjögren’s syndrome and associated xerostomia or xerophthalmia


  • • On October 31, 2018, MeiraGTx announced an exclusive licensing agreement with the National Institute of Dental and Craniofacial Research (NIDCR), a division of the National Institutes of Health (NIH). Under the agreement, MeiraGTx will receive worldwide rights to adeno-associated virus vector mediated gene delivery of aquaporin-1, designated AAV-AQP1, for Sjögren’s syndrome patients with associated xerostomia (dry mouth) or xerophthalmia (dry eyes). The license agreement includes standard and customary US Government terms and provisions.
  • MeiraGTx and the NIDCR are currently partnered in two cooperative research and development agreements (CRADAs), one supporting preclinical work investigating AAV-AQP1 as a treatment for inadequate salivary gland function associated with Sjögren’s syndrome, and the other covering an ongoing Phase 1 dose escalation clinical study of AAV-AQP1 in patients with grade 2 or 3 radiation-induced xerostomia.

Financial terms:

Latest news:

Is general: Yes